The Israeli biomedical company Pluristem is engaged in the development of the drug for radiation sickness and diseases caused by radiation treatment of oncological diseases. The basis of preparation — the stem cells that have undergone special treatment.
The company was founded 12 years ago. Currently, the plant in Haifa employs 180 professionals. 10-th channel ITV, recalls that five years ago, the United States Department of health has invested in an Israeli company $ 25 million.
Wednesday, August 16, it became known that Israeli development is interested in the U.S. Department of defense, expressing its readiness to Finance the final testing phase of the drug LX-R18. After this news the company’s shares on the stock exchange of tel Aviv grew by 8%.
The Marker notes that the company Pluristem has not released the amount you are willing to put the Pentagon in drug tests. However, according to the experts, we are talking about millions of dollars.
To discuss visit NEWSru.co.il in Facebook